Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3- Octreotide: Preliminary report in cancer patients

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 6, 1999, Pages 477-483

  Paganelli, G ^a   Zoboli, S ^a   Cremonesi, M ^a   Macke H R ^b   Chinol, M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

90Y 111In DOTATOC; Peptide receptor radiotherapy; Somatostatin analogue

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; OCTREOTIDE; PHENYLALANINE; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; TYROSINE; YTTRIUM 90;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; BONE MARROW TOXICITY; CANCER PATIENT; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HYDROPHOBICITY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RECEPTOR AFFINITY; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 0033396445     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.477     Document Type: Article

References (27)

1. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731.
2. Reubi JC, Horisberger U, Lang W, et al. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 1989;134:337-344.
3. Foekens JA, Portengen H, van Putten WLJ, et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin and epidermal growth factor in human breast cancer. Cancer 1989;49:7002-7009.
4. Lipp RW, Silly H, Ranner G, et al. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. J Nucl Med 1995;36:13-18.
5. Stolz B, Smith-Jones PM, Albert R, et al. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion 1996;57:17-21.
6. Krenning EP, Kooij PPM, Pauwels S, et al. Somatostatin receptor scintigraphy and radionuclide therapy. Digestion 1996;57:57-61.
7. Lamberts SW, van der Lely AJ, De Herder WW, et al. Drug therapy-Octreotide. N Engl J Med 1996;334: 246-254.
8. Hofland LJ, Lamberts SW. Somatostatin receptors and disease: role of receptor subtypes. Clin Endocrinol Metab 1996; 10:163-76.
9. Bruns C, Dietl MM Palacios JM, et al. Identification and characterization of somatostatin receptors in neonatal rat long bones. Biochem J 1990; 265:39-44.
10. Otte A, Jermann E, Behe M, et al. DOTATOC: - a new powerful tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24:792-795.
11. 3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy Int J Cancer 1998; 75: 406-411.
12. Mäcke, Béhé M, Froidevaux S, et al. DOTA-D-Phe(1)-Tyr(3)-octreotide (DOTATOC): a unique somatostatin receptor ligand for labeling with a variety of metallic radionuclides. J Nucl Med 1997; 38:18P.
13. 90Y-SMT487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 1998; 25: 668-674.
14. Béhé M, Heppeler A, Maecke HR. New somatostatin analogs for SPECT and PET. Eur J Nucl Med 1996; 23: 1144.
15. 1] octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumours: synthesis, radiolabelling and in vitro validation. Life Sci 1991; 49: 1583-1591.
16. Stabin MG, Kooij PPM, Bakker WH, et al. Radiation dosimetry for Indium-111-Pentetreotide. J Nucl Med 1997; 38: 1919-1922.
17. Foster D, Barret P. Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. In: Proc. Sixth International Radiopharmaceutical. Dosimetry Symposium, Oak Ridge Institute for Science and Education, 1998.
18. Virgolini I, Szilvasi I, Kurtaran A, et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998; 39:1928-36.
19. Stabin MG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-546.
20. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
21. 90Y-DOTATOC. Eur J Nucl Med 1999;26:877-886.
22. Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417-418.
23. Kosmas C, Snook D, Gooden CS, et al. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 1992; 52: 904-911.
24. Kooij PP, De Jong M, Boonzaaijer M, et al. The consequences of the effect of cold octreotide treatment on petptide receptor radionuclide therapy with [In-111-DTPA-D-Phe1]-octreotide. Eur J Nucl Med 1998;25: 884.
25. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 1997;80(12 Suppl):2591-2610.
26. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labeled somatostatin analogue. Br J Cancer 1993; 67(6):1437-1439.
27. Dailey MO, Coleman CN, Kaplan HS. Radiation-induced splenic atrophy in patients with Hodgkin's disease and non-Hodgkin's lymphomas. N Eng J Med 1980; 302(4): 215-217.